Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | SENIOR VICE PRESIDENT | February 28, 2023 | March 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date February 28, 2023 · Filed March 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 71,366 |
Ending reported balance
After 2023-03-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-02-28 · Tax withholding · Disposed 5,598 · Balance 72,564 Row 2 · 2023-03-01 · Sale · Disposed 1,198 · Balance 71,366 |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 652 |
Reported balance
Holding disclosure · report date 2023-02-28 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 652 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of February 28, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of February 28, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2023 Filed Mar 3, 2023 00:59 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,198 | $100.70 | $120,638.60 |
DisclosureSEC source: 0001415889-23-003922 · form4-03032023_120354.xml · nonDerivative · entry 2 Watkin Jared · CIK 0001645118 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,366 Read SEC document |
| February 28, 2023 Filed Mar 3, 2023 00:59 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 5,598 | $99.77 | $558,512.46 |
DisclosureSEC source: 0001415889-23-003922 · form4-03032023_120354.xml · nonDerivative · entry 1 Watkin Jared · CIK 0001645118 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,564 Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 00:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 45,812 | $0.00 Strike: $106.24 | $0.00 |
DisclosureSEC source: 0001415889-23-003072 · form4-02232023_120203.xml · derivative · entry 3 Watkin Jared · CIK 0001645118 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,812 Underlying: Common Shares · 45,812 shares Expires 2033-02-16 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 15,270 on February 17, 2024, 15,271 on February 17, 2025, and 15,271 on February 17, 2026. Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 00:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 11,617 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-003072 · form4-02232023_120203.xml · nonDerivative · entry 1 Watkin Jared · CIK 0001645118 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,162 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 01:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,038 | $118.10 | $122,588.84 |
DisclosureSEC source: 0001415889-22-002203 · form4-03022022_050343.xml · nonDerivative · entry 2 Watkin Jared · CIK 0001645118 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,545 Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 01:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 6,759 | $122.41 | $827,369.19 |
DisclosureSEC source: 0001415889-22-002203 · form4-03022022_050343.xml · nonDerivative · entry 1 Watkin Jared · CIK 0001645118 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,583 Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 67,850 | $0.00 Strike: $117.58 | $0.00 |
DisclosureSEC source: 0001415889-22-001748 · form4-02232022_050235.xml · derivative · entry 3 Watkin Jared · CIK 0001645118 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,850 Underlying: Common Shares · 67,850 shares Expires 2032-02-17 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 22,616 on February 18, 2023, 22,617 on February 18, 2024, and 22,617 on February 18, 2025. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 14,559 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-001748 · form4-02232022_050235.xml · nonDerivative · entry 1 Watkin Jared · CIK 0001645118 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,342 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| April 30, 2021 Filed May 4, 2021 23:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy · Derivative | 68,000 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001415889-21-002268 · form4-05042021_040530.xml · derivative · entry 7 Watkin Jared · CIK 0001645118 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,987 Underlying: Common Shares · 68,000 shares Expires 2028-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 30, 2021 Filed May 4, 2021 23:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 17,043 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001415889-21-002268 · form4-05042021_040530.xml · derivative · entry 6 Watkin Jared · CIK 0001645118 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 17,043 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 30, 2021 Filed May 4, 2021 23:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 85,043 | $119.89 | $10,195,626.68 |
DisclosureSEC source: 0001415889-21-002268 · form4-05042021_040530.xml · nonDerivative · entry 4 Watkin Jared · CIK 0001645118 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,783 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.38 to $120.13, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 30, 2021 Filed May 4, 2021 23:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 68,000 | $59.94 | $4,075,920.00 |
DisclosureSEC source: 0001415889-21-002268 · form4-05042021_040530.xml · nonDerivative · entry 3 Watkin Jared · CIK 0001645118 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,826 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2021 Filed May 4, 2021 23:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 17,043 | $44.40 | $756,709.20 |
DisclosureSEC source: 0001415889-21-002268 · form4-05042021_040530.xml · nonDerivative · entry 2 Watkin Jared · CIK 0001645118 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,826 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2021 Filed May 4, 2021 23:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 9,533 | $120.02 | $1,144,112.53 |
DisclosureSEC source: 0001415889-21-002268 · form4-05042021_040530.xml · nonDerivative · entry 1 Watkin Jared · CIK 0001645118 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,783 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.0103 to $120.08, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 01:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,391 | $120.61 | $167,768.51 |
DisclosureSEC source: 0001415889-21-001215 · form4-03022021_050325.xml · nonDerivative · entry 2 Watkin Jared · CIK 0001645118 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,316 Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 01:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 9,433 | $121.58 | $1,146,864.14 |
DisclosureSEC source: 0001415889-21-001215 · form4-03022021_050325.xml · nonDerivative · entry 1 Watkin Jared · CIK 0001645118 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,707 Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 00:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 58,659 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000902 · form4-02232021_040207.xml · derivative · entry 3 Watkin Jared · CIK 0001645118 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,659 Underlying: Common Shares · 58,659 shares Expires 2031-02-18 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 19,553 on February 19, 2022, 19,553 on February 19, 2023, and 19,553 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 00:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 11,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000902 · form4-02232021_040207.xml · nonDerivative · entry 1 Watkin Jared · CIK 0001645118 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,140 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 21:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 8,248 | $82.00 | $676,336.00 |
DisclosureSEC source: 0001179110-20-003412 · edgar.xml · nonDerivative · entry 1 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,696 Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 22:19 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,761 | $77.89 | $137,164.29 |
DisclosureSEC source: 0001179110-20-002898 · edgar.xml · nonDerivative · entry 2 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,944 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:19 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 8,330 | $79.19 | $659,652.70 |
DisclosureSEC source: 0001179110-20-002898 · edgar.xml · nonDerivative · entry 1 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,705 Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 76,198 | $0.00 Strike: $87.72 | $0.00 |
DisclosureSEC source: 0001179110-20-002276 · edgar.xml · derivative · entry 3 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,198 Underlying: Common shares · 76,198 shares Expires 2030-02-20 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 25,399 on February 21, 2021, 25,399 on February 21, 2022, and 25,400 on February 21, 2023. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002276 · edgar.xml · nonDerivative · entry 1 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,035 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 50,994 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001179110-19-005605 · edgar.xml · derivative · entry 10 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,987 Underlying: Common shares · 50,994 shares Expires 2028-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 34,086 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001179110-19-005605 · edgar.xml · derivative · entry 9 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,043 Underlying: Common shares · 34,086 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 109,657 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-19-005605 · edgar.xml · derivative · entry 8 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 109,657 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 114,692 | $0.00 Strike: $48.04 | $0.00 |
DisclosureSEC source: 0001179110-19-005605 · edgar.xml · derivative · entry 7 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 114,692 shares Expires 2025-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 309,429 | $78.51 | $24,294,199.08 |
DisclosureSEC source: 0001179110-19-005605 · edgar.xml · nonDerivative · entry 5 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,535 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.50 to $78.62, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 50,994 | $59.94 | $3,056,580.36 |
DisclosureSEC source: 0001179110-19-005605 · edgar.xml · nonDerivative · entry 4 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 383,964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 34,086 | $44.40 | $1,513,418.40 |
DisclosureSEC source: 0001179110-19-005605 · edgar.xml · nonDerivative · entry 3 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,970 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 109,657 | $38.40 | $4,210,828.80 |
DisclosureSEC source: 0001179110-19-005605 · edgar.xml · nonDerivative · entry 2 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 114,692 | $48.04 | $5,509,803.68 |
DisclosureSEC source: 0001179110-19-005605 · edgar.xml · nonDerivative · entry 1 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,227 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:33 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,391 | $78.00 | $108,498.00 |
DisclosureSEC source: 0001179110-19-003126 · edgar.xml · nonDerivative · entry 2 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,535 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 22:33 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 8,464 | $77.23 | $653,674.72 |
DisclosureSEC source: 0001179110-19-003126 · edgar.xml · nonDerivative · entry 1 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,926 Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 108,770 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001179110-19-002648 · edgar.xml · derivative · entry 3 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,770 Underlying: Common shares · 108,770 shares Expires 2029-02-21 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 36,256 on February 22, 2020, 36,257 on February 22, 2021, and 36,257 on February 22, 2022. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 20,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002648 · edgar.xml · nonDerivative · entry 1 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,390 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 22:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 65,000 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-18-012610 · edgar.xml · derivative · entry 4 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,657 Underlying: Common shares · 65,000 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. F3 · derivative.exercise_date: Options for these shares became exercisable on 02/19/2017 and 02/19/2018. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 22:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 65,000 | $71.00 | $4,615,000.00 |
DisclosureSEC source: 0001179110-18-012610 · edgar.xml · nonDerivative · entry 2 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,640 Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 22:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 65,000 | $38.40 | $2,496,000.00 |
DisclosureSEC source: 0001179110-18-012610 · edgar.xml · nonDerivative · entry 1 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,640 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,875 | $62.96 | $118,050.00 |
DisclosureSEC source: 0001179110-18-008792 · edgar.xml · nonDerivative · entry 1 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,640 Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 22:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 727 | $61.20 | $44,488.77 |
DisclosureSEC source: 0001179110-18-003976 · edgar.xml · nonDerivative · entry 4 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,515 Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 22:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,573 | $61.19 | $96,256.59 |
DisclosureSEC source: 0001179110-18-003976 · edgar.xml · nonDerivative · entry 3 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,242 Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 22:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $61.19 | $24,476.40 |
DisclosureSEC source: 0001179110-18-003976 · edgar.xml · nonDerivative · entry 2 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,815 Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 22:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $61.19 | $18,357.00 |
DisclosureSEC source: 0001179110-18-003976 · edgar.xml · nonDerivative · entry 1 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,215 Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 22:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 370 | $58.90 | $21,793.74 |
DisclosureSEC source: 0001179110-18-003317 · edgar.xml · nonDerivative · entry 4 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,515 Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 22:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $58.86 | $11,771.00 |
DisclosureSEC source: 0001179110-18-003317 · edgar.xml · nonDerivative · entry 3 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,885 Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 22:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 426 | $58.85 | $25,070.53 |
DisclosureSEC source: 0001179110-18-003317 · edgar.xml · nonDerivative · entry 2 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,085 Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 3,866 | $60.55 | $234,086.30 |
DisclosureSEC source: 0001179110-18-003317 · edgar.xml · nonDerivative · entry 1 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,511 Read SEC document |
| February 20, 2018 Filed Feb 21, 2018 23:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $59.29 | $11,858.20 |
DisclosureSEC source: 0001179110-18-002514 · edgar.xml · nonDerivative · entry 4 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,377 Read SEC document |
| February 20, 2018 Filed Feb 21, 2018 23:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 97 | $59.29 | $5,751.14 |
DisclosureSEC source: 0001179110-18-002514 · edgar.xml · nonDerivative · entry 3 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,577 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.